Furthermore, we corroborated our findings with a second analysis in participants with type 2 diabetes that underwent intravenous high-dose infusions of GLP-1(7–36)-amide, GIP, GLP-1/GIP combination, or placebo. Here, GIP is linked to type 2 diabetes mellitus.